103 related articles for article (PubMed ID: 3906779)
21. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
Sakatani A; Miyagawa Y; Takemura N
J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
[TBL] [Abstract][Full Text] [Related]
22. Effect of antihypertensive therapy on aortic distensibility in patients with essential hypertension: comparison with trichlormethiazide, nicardipine and alacepril.
Honda T; Hamada M; Shigematsu Y; Matsumoto Y; Matsuoka H; Hiwada K
Cardiovasc Drugs Ther; 1999 Jul; 13(4):339-46. PubMed ID: 10516870
[TBL] [Abstract][Full Text] [Related]
23. Drug protein conjugates--I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat.
Park BK; Grabowski PS; Yeung JH; Breckenridge AM
Biochem Pharmacol; 1982 May; 31(9):1755-60. PubMed ID: 7049181
[TBL] [Abstract][Full Text] [Related]
24. [Synthesis of angiotensin converting enzyme inhibitor, captopril ester derivatives].
Wu M; Xie MH; Zhao DY; Chen GY; Wang YC; Kong H
Yao Xue Xue Bao; 1988; 23(12):890-4. PubMed ID: 3076736
[No Abstract] [Full Text] [Related]
25. Renal effects of alacepril in essential hypertension.
Tomita K; Nonoguchi H; Terada Y; Marumo F
J Cardiovasc Pharmacol; 1992 Oct; 20(4):520-4. PubMed ID: 1280705
[TBL] [Abstract][Full Text] [Related]
26. Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure.
Kinugawa T; Osaki S; Kato M; Ogino K; Shimoyama M; Tomikura Y; Igawa O; Hisatome I; Shigemasa C
Clin Exp Pharmacol Physiol; 2002 Dec; 29(12):1060-5. PubMed ID: 12390293
[TBL] [Abstract][Full Text] [Related]
27. Effect of alacepril on 24-hour blood pressure in elderly hypertensive patients.
Kohara K; Hara-Nakamura N; Takada Y; Iwata T; Ochi T; Kukita H; Muneta S; Hiwada K
Int J Clin Pharmacol Ther; 1996 Sep; 34(9):380-3. PubMed ID: 8880286
[TBL] [Abstract][Full Text] [Related]
28. Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension.
Kinugawa T; Kitamura H; Ogino K; Noguchi N; Matsumoto T; Hisatome I; Miyakoda H; Kotake H; Mashiba H
Br J Clin Pharmacol; 1992 Oct; 34(4):366-9. PubMed ID: 1457272
[TBL] [Abstract][Full Text] [Related]
29. Effects of the angiotensin-converting enzyme inhibitor alacepril in dogs with mitral valve disease.
Hori Y; Nakamura K; Kanno N; Hitomi M; Yamashita Y; Hosaka S; Isayama N; Mimura T
J Vet Med Sci; 2018 Aug; 80(8):1212-1218. PubMed ID: 29937457
[TBL] [Abstract][Full Text] [Related]
30. Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment.
Murohara T; Tayama S; Tabuchi T; Sumida H; Honda T; Hayasaki K; Yasue H
Am J Cardiol; 1996 Jun; 77(14):1159-63. PubMed ID: 8651088
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states.
Onoyama K; Hirakata H; Tsuruda H; Ohchi N; Tomooka S; Motomura K; Omae T; Hayashi K; Fujishima M
Clin Pharmacol Ther; 1985 Oct; 38(4):462-8. PubMed ID: 3899460
[TBL] [Abstract][Full Text] [Related]
32. Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure.
Kinugawa T; Kato M; Mori M; Endo A; Kato T; Hamada T; Noguchi N; Omodani H; Osaki S; Ogino K; Miyakoda H; Hisatome I; Shigemasa C
Eur J Clin Pharmacol; 1998 May; 54(3):209-14. PubMed ID: 9681661
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of latent diabetic nephropathy with ACE inhibitor alacepril].
Hashimoto T
Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):549-56. PubMed ID: 1920934
[TBL] [Abstract][Full Text] [Related]
34. The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha.
Shimozawa M; Naito Y; Manabe H; Uchiyama K; Katada K; Kuroda M; Nakabe N; Yoshida N; Yoshikawa T
Redox Rep; 2004; 9(6):354-9. PubMed ID: 15720832
[TBL] [Abstract][Full Text] [Related]
35. Role of renin-angiotensin and kallikrein-kinin systems on the mechanism of the hypotensive effects of converting enzyme inhibitor, alacepril.
Tanaka S; Shimamoto K; Ando T; Nakahashi Y; Ura N; Hosoda S; Ishida H; Yamaji I; Yokoyama T; Masuda A
Clin Exp Hypertens A; 1987; 9(2-3):605-9. PubMed ID: 3038424
[TBL] [Abstract][Full Text] [Related]
36. Effects of acute and chronic alacepril treatment on exercise capacity and hemodynamics in patients with heart failure: a preliminary study.
Osaki S; Kinugawa T; Ogino K; Kato M; Furuse Y; Tomikura Y; Igawa O; Hisatome ; Shigemasa C
Int J Clin Pharmacol Ther; 2002 Feb; 40(2):69-74. PubMed ID: 11862975
[TBL] [Abstract][Full Text] [Related]
37. Effects of an angiotensin-converting enzyme inhibitor, alacepril, on cardiovascular and sympathetic nervous responses to mental stress in patients with essential hypertension.
Saitoh M; Miyakoda H; Kitamura H; Kinugawa T; Kotake H; Mashiba H
Intern Med; 1993 Sep; 32(9):691-4. PubMed ID: 8142672
[TBL] [Abstract][Full Text] [Related]
38. Metabolism of captopril-L-cysteine, a captopril metabolite, in rats and dogs.
Kripalani KJ; Dean AV; Migdalof BH
Xenobiotica; 1983 Dec; 13(12):701-5. PubMed ID: 6372264
[TBL] [Abstract][Full Text] [Related]
39. [Synthesis of carbon-14 labeled 1-acetoxyethyl 2-(2-fluoro-4-biphenyl)propionate (14C-FP 83)].
Uchida K; Konishi Y
Radioisotopes; 1988 Dec; 37(12):674-6. PubMed ID: 3252359
[TBL] [Abstract][Full Text] [Related]
40. [The effect of alacepril on insulin sensitivity in patients with essential hypertension].
Seta T; Fujii S; Nishizawa M; Miwa U; Nakabayashi H; Takeda R
Nihon Naibunpi Gakkai Zasshi; 1993 Mar; 69(3):158-65. PubMed ID: 8467930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
